Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;39(3):272-277.
doi: 10.2337/cd21-0027.

Increasing Insulin Pump Use Among 12- to 26-Year-Olds With Type 1 Diabetes: Results From the T1D Exchange Quality Improvement Collaborative

Sarah K Lyons  1 , Osagie Ebekozien  2   3 , Ashley Garrity  4 , Don Buckingham  5 , Ori Odugbesan  2 , Sarah Thomas  6 , Nicole Rioles  2 , Kathryn Gallagher  7 , Rona Y Sonabend  1 , Ilona Lorincz  7 , G Todd Alonso  6 , Manmohan K Kamboj  5 , Joyce M Lee  4 ; T1D Exchange Quality Improvement Collaborative Study Group
Affiliations

Increasing Insulin Pump Use Among 12- to 26-Year-Olds With Type 1 Diabetes: Results From the T1D Exchange Quality Improvement Collaborative

Sarah K Lyons et al. Clin Diabetes. 2021 Jul.

Abstract

Insulin pump therapy in pediatric type 1 diabetes has been associated with better glycemic control than multiple daily injections. However, insulin pump use remains limited. This article describes an initiative from the T1D Exchange Quality Improvement Collaborative aimed at increasing insulin pump use in patients aged 12-26 years with type 1 diabetes from a baseline of 45% in May 2018 to >50% by February 2020. Interventions developed by participating centers included increasing in-person and telehealth education about insulin pump technology, creating and distributing tools to assist in informed decision-making, facilitating insulin pump insurance approval and onboarding processes, and improving clinic staff knowledge about insulin pumps. These efforts yielded a 13% improvement in pump use among the five participating centers, from 45 to 58% over 22 months.

PubMed Disclaimer

Conflict of interest statement

O.E. is a compensated Health Equity Advisory Board member for Medtronic Diabetes and serves as the principal investigator for investigator-led projects sponsored by Abbott, Dexcom, Eli Lilly, Insulet, and Medtronic. J.M.L. is on the medical advisory board for GoodRx. No other potential conflicts of interest relevant to this article were reported.

Figures

FIGURE 1
FIGURE 1
Insulin pump therapy key driver diagram.
See this image and copyright information in PMC

References

    1. Berget C, Messer LH, Forlenza GP. A clinical overview of insulin pump therapy for the management of diabetes: past, present, and future of intensive therapy. Diabetes Spectr 2019;32:194–204 - PMC - PubMed
    1. Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010(1):CD005103. - PubMed
    1. Pala L, Dicembrini I, Mannucci E. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetol 2019;56:973–980 - PubMed
    1. Pihoker C, Badaru A, Anderson A, et al. .; SEARCH for Diabetes in Youth Study Group . Insulin regimens and clinical outcomes in a type 1 diabetes cohort: the SEARCH for Diabetes in Youth study. Diabetes Care 2013;36:27–33 - PMC - PubMed
    1. Karges B, Schwandt A, Heidtmann B, et al. . Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA 2017;318:1358–1366 - PMC - PubMed